Neogen Corporation develops, manufactures, and markets products and services for food and animal safety in the United States and internationally. It operates through the Food Safety and Animal Safety segments. The Food Safety segment offers diagnostic test kits and related products to detect substances such as foodborne pathogens, spoilage organisms, natural toxins, food allergens, drug residues, and pesticide residues in human food and animal feed. The Animal Safety segment provides veterinary instruments, delivery systems, nutritional supplements, parasiticides, rodent and insect control products, and genomic testing and software services. Neogen was incorporated in 1981 and is headquartered in Lansing, Michigan.
Neogen Set to Report Earnings Tuesday After Last Quarter's Revenue Beat
Neogen will report its latest quarterly earnings this Tuesday after market hours, with Wall Street expecting revenue to be flat year on year. The life sciences company beat analysts' revenue expectations last quarter, posting revenues of $225.3 million, flat year on year, and also topped analysts' EPS estimates while its full-year revenue guidance exceeded expectations. The flat revenue expected this quarter would mark an improvement from the 3.6% decrease Neogen recorded in the same quarter last year. Analysts covering the company have generally reconfirmed their estimates over the last 30 days, though Neogen has missed Wall Street's revenue estimates multiple times over the last two years. Neogen is the first among its peers to report earnings this season, and its shares are up 3.4% over the last month while the broader healthcare equipment and supplies segment has been flat.
Neogen Shares Fall 5.4% After FDA Warning Letters Over Contaminated Veterinary Product
Neogen shares fell 5.4% in the afternoon session after the U.S. Food and Drug Administration issued warning letters to the company following laboratory tests that uncovered fungal contamination in its veterinary product HYCOAT. The FDA said tests identified multiple fungal species in Neogen Vet HYCOAT, a product marketed as sterile, and the contamination caused severe joint infections in nearly 100 horses and resulted in at least 20 horse deaths. The incident represents the highest number of horse fatalities ever linked to a quality issue in an FDA-regulated veterinary product. Neogen's shares are very volatile and have had 22 moves greater than 5% over the last year, and the stock is up 82.5% since the beginning of the year, trading at $12.77 per share close to its 52-week high of $13.98.
NEOG · Regulation · Negative FDA warning letters over fungal contamination in Neogen Vet HYCOAT, linked to horse infections and deaths, hit the company directly.
Neogen Plans 50% R&D Increase as Petrifilm Manufacturing Moves In-House
Neogen Corporation is raising fiscal 2027 research and development spending by about 50% as it expands its food and animal safety pipeline and brings Petrifilm manufacturing in-house at its Lansing facility. The company expects to complete validation of the first Petrifilm SKU by the end of August 2026, with sellable production and a multi-quarter manufacturing transition beginning in November 2026, and it plans at least two Petrifilm SKU launches annually with at least five candidates identified. Neogen's Animal Safety business entered fiscal 2027 with most third-party supplier issues resolved, after fourth-quarter fiscal 2026 revenues fell 8.2% year over year while core revenues rose 0.5% and sales increased more than 7% sequentially. Neogen ended fiscal 2026 with $185.5 million in cash against about $800 million in debt, and plans to use roughly $140 million of expected net Genomics proceeds primarily for debt reduction. Over the past 30 days, the Zacks Consensus Estimate for Neogen's fiscal 2027 earnings has risen 3.3% to 31 cents, while the consensus mark for fiscal 2027 revenues is pegged at $883.2 million, suggesting a 1.5% rise from the prior year.
NEOG · Capital · Positive Neogen plans to use ~$140M of expected net Genomics proceeds primarily for debt reduction, and its FY2027 EPS estimate rose 3.3%.
NEOG · Technology · Positive Neogen is raising fiscal 2027 R&D spending ~50% and bringing Petrifilm manufacturing in-house with multiple SKU launches planned.
Glucotrack, Bausch Health, Corcept Lead Biotech Surge on Pipeline and Earnings News
Glucotrack, Bausch Health, and Corcept Therapeutics were among Thursday's top biotech gainers, driven by pipeline progress and strong financial results. Glucotrack's subsidiary Lokahi Therapeutics advanced development of LT-100, a non-narcotic therapy derived from honeybee venom, with plans to begin clinical evaluation of a simplified single-injection method as early as the fourth quarter of 2026, sending shares up 173.68% to $0.78. Bausch Health raised its full-year 2026 revenue outlook to between $10.790 billion and $11.040 billion after reporting second-quarter consolidated revenue of $2.85 billion, a 13% increase, and its stock rose 28.85% to $6.03. Corcept Therapeutics posted second-quarter net income of $43.0 million on revenue of $256.1 million, including $208.6 million from Korlym and its authorized generic and $47.6 million from newly launched Lifyorli, and lifted its 2026 revenue forecast to $1.1 billion to $1.2 billion, pushing shares up 27.29% to $118.32. Nuwellis surged 135.45% to $4.45 after a study on its Aquadex therapy was accepted by a peer-reviewed journal, while Neogen touched a 52-week high of $11.56 and closed up 22.26% at $11.53 following its fiscal 2026 results and fiscal 2027 guidance.
Neogen Reports Q4 Revenue of $225.3 Million, Core Growth Accelerates to 4.3%
Neogen reported fiscal fourth-quarter revenue of $225.3 million, with core revenue growth accelerating to 4.3%, its highest rate of fiscal 2026. Food safety revenue totaled $166.8 million and grew 5.8% on a core basis, while adjusted EBITDA rose 12% to $45.4 million. For fiscal 2027, the company forecast revenue of $880 million to $885 million and adjusted EBITDA of $180 million to $182 million, while planning to increase R&D spending by about 50% and invest $25 million in transformation initiatives. Neogen also repaid $20 million of its term loan and expects to use approximately $140 million from the planned Genomics business sale to repay debt and fund investments.
Animal Genetics Market Size to Reach USD 13.90 Billion by 2035
The global animal genetics market is projected to grow from USD 7.32 billion in 2025 to USD 13.90 billion by 2035, at a compound annual growth rate of 6.62 percent, according to a new report by SNS Insider. The genomic and genetic testing segment held the largest share at 48.2 percent in 2025 and is expected to grow at a CAGR of 7.3 percent, while the cattle segment accounted for about 45.5 percent of the market. North America led with a 37.5 percent share in 2025, and the Asia Pacific region is forecast to be the fastest-growing market at a CAGR of 8.4 percent. Key companies include Genus plc, Neogen Corporation, URUS Group, Zoetis Inc., and EW Group.
Neogen Shares Surge 101.1% in a Year, Outpacing Industry Decline
Neogen Corporation shares have surged 101.1% over the past year, sharply outperforming its industry's 30.4% decline and the S&P 500's 22.5% gain. The rally has been driven by strength in the Food Safety segment, where third-quarter fiscal 2026 revenues reached 157.6 million dollars with core revenue growth of 4%, supported by indicator testing, culture media, and pathogen test kits. The company also raised its full-year fiscal 2026 revenue guidance to a range of 857 million to 860 million dollars, up from 845 million to 855 million dollars. Recent product launches, including the Neogen MPNTray water testing system and the Listeria Right Now assay, along with progress integrating the former 3M Food Safety business, have bolstered investor confidence. However, Neogen faces headwinds from input cost inflation, global logistics disruptions, and freight cost increases of 1.5 million dollars per quarter, while carrying 793 million dollars in total outstanding debt against 159.9 million dollars in cash.
United States